SCHEMBL311052

SCHEMBL311052

CCC(=O)OS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KMT2A Q03164 4/20 0.45
GAA P10253 2/20 0.44
LMNA P02545 3/20 0.43
STAT3 P40763 1/20 0.42
F2 P00734 2/20 0.42
PRSS1 P07477 2/20 0.42
PRSS2 P07478 2/20 0.42
PRSS3 P35030 2/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Choline SCHEMBL6362242 0.88 ALDH1A1 (0.43) ALDH1A1KMT2AGAALMNASTAT3
SCHEMBL4881543 0.87 ALDH1A1 (0.55) ALDH1A1KMT2AGAALMNASTAT3
SCHEMBL8842257 0.86 ALDH1A1 (0.50) ALDH1A1KMT2AGAALMNASTAT3
SCHEMBL5685915 0.84 ALDH1A1 (0.56) ALDH1A1KMT2AGAASTAT3F2
SCHEMBL493092 0.84 ALDH1A1 (0.51) ALDH1A1KMT2AGAASTAT3F2
SCHEMBL27297266 0.84 ALDH1A1 (0.51) ALDH1A1KMT2AGAALMNASTAT3
SCHEMBL4201426 0.83 ALDH1A1 (0.50) ALDH1A1KMT2AGAASTAT3F2
SCHEMBL6543497 0.83 HSD11B1 (0.50) ALDH1A1KMT2ASMN1; SMN2
SCHEMBL28069479 0.83 ALDH1A1 (0.47) ALDH1A1KMT2AGAALMNASTAT3
SCHEMBL27659885 0.83 ALDH1A1 (0.47) ALDH1A1KMT2AGAALMNASTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111655680-B Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders 阿德利克斯股份有限公司 2024-03-05 CN disclosed
CN-113453724-A Sulfonylmaleimide-based linkers and corresponding conjugates 皮埃尔法布雷医药公司 2021-09-28 CN disclosed
CN-104945404-B A kind of preparation method of N- propenecarbonyls piperidine derivative 广东东阳光药业有限公司 2018-09-14 CN disclosed
CN-106132972-B Phosphoramidate for treating HCV infection 银杏树药业(苏州)有限公司 2018-08-31 CN disclosed
CN-104945404-A Method for preparing N-propylene carbonyl piperidine derivative GUANGDONG HEC PHARMACEUTICAL 2015-09-30 CN disclosed
CN-102863510-B N (2)-L-alanyl-L-glutamine synthetic method SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD 2014-06-04 CN disclosed
US-8724296-B2 Solid electrolytic capacitor and fabrication method thereof SANYO ELECTRIC CO., LTD. (JP) 2014-05-13 US disclosed
US-8425805-B2 Conductive polymer film, electronic device, and methods of producing the film and the device SANYO ELECTRIC CO., LTD. (JP) 2013-04-23 US disclosed
CN-102863510-A N (2)-L-alanyl-L-glutamine synthetic method SHANDONG JINCHENG PHARMACEUTICAL & CHEMICAL CO LTD 2013-01-09 CN disclosed
US-20120049136-A1 CONDUCTIVE POLYMER FILM, ELECTRIC DEVICES AND METHODS FOR MANUFACTURING THE CONDUCTIVE POLYMER FILM SANYO ELECTRIC CO., LTD. (JP) 2012-03-01 US disclosed
WO-2004064762-A9 NOVEL COCRYSTALLIZATION S S C I INC (US) 2006-07-27 WO disclosed
EP-1596869-A2 NOVEL COCRYSTALLIZATION S.S.C.I., Inc (US) 2005-11-23 EP disclosed
WO-2005089375-A2 SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND S.S.C.I., INC. (US) 2005-09-29 WO disclosed
WO-2004064762-A2 NOVEL COCRYSTALLIZATION S.S.C.I. INC. (US) 2004-08-05 WO disclosed
US-20040106808-A1 Processes for preparing calanolide a and intermediates thereof SAGAMI CHEMICAL RESEARCH CENTER (JP) 2004-06-03 US disclosed
EP-1352907-A1 PROCESSES FOR PREPARING CALANOLIDE A AND INTERMEDIATES THEREOF KURARAY CO., LTD. (JP) 2003-10-15 EP disclosed
EP-0916654-A1 SULFONIC ESTER DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND USE THEREOF KANEKA CORPORATION (JP) 1999-05-19 EP disclosed
US-4943514-A POLYMERIC MORDANT FROM QUATERNIZED VINYLIMIDAZOLE EASTMAN KODAK COMPANY (US) 1990-07-24 US disclosed
US-4942103-A POLYVINYL ALCOHOL BINDERS, RADIATION SENSITIVE DICHROMATES, A POLYMERIC MORDANT OF QUATERNIZED N-VINYLIMIDAZOLES EASTMAN KODAK COMPANY (US) 1990-07-17 US disclosed
CN-86103619-A The preparation method of the bicyclic pyrazolidinones that 7-replaces 1986-10-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106808-A1 Processes for preparing calanolide a and intermediates thereof CALR, CYP51A1, CYP4A11 ALDH1A1 1043/4885KMT2A 3255/4885GAA 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.